Health
AbbVie raises sales forecast for new immunology drugs to $27 billion in 2027
AbbVie has raised its 2027 sales forecast for its immunology drugs Skyrizi and Rinvoq to $27 billion, up $6 billion from its previous forecast. The
Trial results show that the second malaria vaccine is highly protective
A malaria vaccine developed by Oxford University and the Indian Serum Institute prevented about three-quarters of symptomatic malaria cases in young children in the first
GSK settles another Zantac lawsuit in California
GSK said it had agreed to settle another California lawsuit alleging that its discontinued heartburn drug Zantac caused cancer. The case, which was due to
Biogen abandons Alzheimer’s drug Aduhelm
Biogen will complete a post-registration study of Aduhelm for the treatment of Alzheimer’s disease and regain licensing rights to the drug after failing to find
US FDA reports 561 deaths linked to Philips machines since 2021
The U.S. Food and Drug Administration said Wednesday there have been 561 deaths since 2021 linked to Philips recalled ventilator and obstructive sleep apnea products.
Novo Nordisk will more than double shipments of lower-dose Wegovi to the US
Novo Nordisk will more than double shipments of lower doses of its obesity drug Wegovy to the U.S. compared with previous months, Chief Executive Officer
Pfizer reported a surprise Q4 profit, but sales of key products fell
Pfizer reported a surprise quarterly profit Tuesday, helped by cost cuts and better-than-expected demand for its COVID drug Paxlovid, but sales of some high-end products
GSK posts strong growth thanks to Haleon spin-off and vaccines push
GSK beat market estimates in its fourth-quarter results and unveiled an upbeat forecast for 2024 and beyond on the acceleration of its vaccines and cancer
Rise in reports of fake weight loss drugs linked to a shortage of real drugs
The World Health Organisation has warned that a global shortage last year of popular diabetes drugs that are also used for weight loss, such as
Gilead Sciences increases stake in oncology company Arcus Biosciences to 33%
Gilead Sciences has announced that it has increased its stake in Arcus Biosciences to 33% and expanded its presence on the company’s board of directors